Identification

Summary

Hydroxyamphetamine is an indirectly acting sympathomimetic agent producing mydriasis for diagnostic purposes.

Brand Names
Paremyd
Generic Name
Hydroxyamphetamine
DrugBank Accession Number
DB09352
Background

Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary stinging in the eyes. The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 151.2056
Monoisotopic: 151.099714043
Chemical Formula
C9H13NO
Synonyms
  • 4-(2-aminopropyl)phenol
  • 4-hydroxyamphetamine
  • dl-4-hydroxyamphetamine
  • dl-p-hydroxyamphetamine
  • Hydroxyamphetamine
  • p-hydroxyamphetamine
External IDs
  • NSC-170995

Pharmacology

Indication

Mydriatic agent (eye pupil dilatation) for diagnosis of ophthalmic nerve lesions.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Hydroxyamphetamine hydrobromide is an indirect acting sympathomimetic agent which causes the release of norepinephrine from adrenergic nerve terminals, resulting in mydriasis.

Absorption

Intended for local use only (ophthalmic use).

Volume of distribution

Intended for local use only (ophthalmic use).

Protein binding

Intended for local use only (ophthalmic use).

Metabolism

Intended for local use only (ophthalmic use).

Route of elimination

Intended for local use only (ophthalmic use).

Half-life

Not Available

Clearance

Intended for local use only (ophthalmic use).

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

No data available.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.
AminophyllineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Aminophylline.
BromotheophyllineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Bromotheophylline.
CaffeineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Caffeine.
DyphyllineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Dyphylline.
EscitalopramThe risk or severity of serotonin syndrome can be increased when Hydroxyamphetamine is combined with Escitalopram.
FenfluramineThe risk or severity of serotonin syndrome can be increased when Hydroxyamphetamine is combined with Fenfluramine.
FluoxetineThe risk or severity of serotonin syndrome can be increased when Hydroxyamphetamine is combined with Fluoxetine.
FormoterolHydroxyamphetamine may increase the sympathomimetic activities of Formoterol.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydroxyamphetamine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Hydroxyamfetamine hydrobromide59IG47SZ0E306-21-8RZCJLMTXBMNRAD-UHFFFAOYSA-N
International/Other Brands
Norveritol / Pulsoton
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ParemydHydroxyamfetamine hydrobromide (10 mg/1mL) + Tropicamide (2.5 mg/1mL)SolutionOphthalmicAkorn, Inc.1992-01-30Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Organopnictogen compounds / Organooxygen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / Amine / Amphetamine or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Hydrocarbon derivative / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
FQR280JW2N
CAS number
103-86-6
InChI Key
GIKNHHRFLCDOEU-UHFFFAOYSA-N
InChI
InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3
IUPAC Name
4-(2-aminopropyl)phenol
SMILES
CC(N)CC1=CC=C(O)C=C1

References

General References
  1. product info [Link]
  2. American Academy of Ophthalmology - Horner syndrome Article [Link]
  3. product info [Link]
Human Metabolome Database
HMDB0060765
PubChem Compound
3651
PubChem Substance
347827833
ChemSpider
3525
BindingDB
81459
RxNav
7839
ChEBI
103855
ChEMBL
CHEMBL1546
Wikipedia
4-Hydroxyamphetamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.13 mg/mLALOGPS
logP0.58ALOGPS
logP1ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)10.48ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area46.25 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity45.69 m3·mol-1ChemAxon
Polarizability17.17 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at November 30, 2015 19:10 / Updated at June 12, 2020 16:52